Experimental Multiple Sclerosis Treatment Frexalimab Shows Impressive Results

Promising new drug significantly reduces MS disease activity, with minimal side effects.

Topline

An experimental multiple sclerosis (MS) drug, frexalimab, demonstrates near-complete suppression of disease activity over two years, showing remarkable effectiveness in clinical trials.

Study Details

Researchers investigated frexalimab, a second-generation anti-CD40 ligand monoclonal antibody, known for modulating both B-cell and T-cell activity w…